Airway Therapeutics is a leading brand that is dedicated to developing a new class of biologics aimed at breaking the cycle of injury and inflammation for patients suffering from respiratory and inflammatory diseases. With a strong focus on innovation and research, Airway Therapeutics offers groundbreaking solutions to improve the lives of those affected by these conditions. One of their remarkable products is AT-100, a novel recombinant human protein called rhSP-D.

AT-100 effectively reduces inflammation and infection while modulating the immune response to interrupt the cycle of injury and inflammation. This innovative therapeutic holds great promise for patients seeking relief from respiratory and inflammatory diseases. Additionally, Airway Therapeutics is actively involved in addressing bronchopulmonary dysplasia (BPD), a respiratory disease that impacts a considerable number of premature infants.

By tackling the root causes of BPD, Airway Therapeutics aims to prevent long-term lung damage, reduce NICU stays, and improve outcomes for these infants. To stay up-to-date with the latest advancements and breakthroughs in the field, Airway Therapeutics regularly shares news and updates about their research and clinical trials. If you're interested in learning more or collaborating with Airway Therapeutics, they welcome inquiries from the scientific, medical, and investment communities.

With their commitment to innovation and improving patient outcomes, Airway Therapeutics is making significant strides in the field of respiratory and inflammatory diseases